10/12/2021 0 Comments Pharmaceutical Regulatory Updates: Part II - A New Approach to Amino-Organic Chemistry Safety TestingPharmaceutical Regulation Updates are released every January and July, giving companies an opportunity to see what changes have been made. There are a number of reasons why this is important. One of the most important reasons is to allow companies to better understand the type of clinical trial they will be conducting in the future. This will also give them an opportunity to better communicate with physicians and other healthcare professionals. The next key reason why it is important to be aware of updates on pharmaceutical regulatory submissions is so that the regulatory agencies can take action. In September, the FDA released a new mandate for manufacturers to submit new and revised labels for pharmaceutical products containing cyprine antibiotics. The FDA calls for manufacturers to add the term "ethynylenediamine" to the front of the label for these medicines. This is the only term that the FDA has authorized to appear in any label for these medicines. In addition to the wording of the new mandate, manufacturers also must include a key phrase in their clinical documents. That key phrase is "class III medical device". The FDA defines class III medical device as one that is manufactured by following the labeling rules of the Food and Drug Administration's (FDA) Code of Federal Regulations for drugs or other pharmaceutical products that are generally recognized as safe under the provisions of the Food Safety Modernization Act (FSMA). The primary purpose of this code is to prevent tainted pharmaceutical products from being sold to patients. For example, there is a certain amount of mercury that is allowed in food that must be taken by anyone who may come in contact with that food, but if a pharmaceutical product is manufactured and marketed without meeting the standards of the FDA's new class III requirements, then the company breaks federal law and could be held accountable for injuries or deaths that resulted from taking the tainted medicine. According to the FDA's guidance, manufacturers are required to submit the new class III medical device labels to the agency by January 1, 26 may be later. The pharmaceutical education for manufacturers is also required to implement quality improvement programs based on the guidelines set forth in the revised regulations. Additionally, manufacturers are required to work with patients and their health care providers to ensure that any concerns they have about their products can be resolved. In addition, they must work to address any adverse events that may occur during the year ahead. Pharmaceutical Regulatory Update: Part II - Subject to Item 5 on the Table of Compliance for New Devices and Submanufactures, the FDA issued new classification guidelines for some medical devices and submanufactures which had not been previously tested against elemental impurities. According to the guidance, manufacturers are not required to test for elemental impurities before releasing new devices for sale. Manufacturers are only required to conduct post-marketing monitoring after the drug product is released for sale. The FDA has determined that it is not necessary for manufacturers to test their products against all identified elemental impurities. Rather, they can address identified risks only if they are likely to cause health problems or cause adverse events. According to the FDA's standpoint, it is likely that a new drug will not cause adverse events or health problems only in the event that no other drugs or other contact with the patient would cause health problems. Accordingly, the agency has determined that it is not necessary to require manufacturers to screen for all possible chemical or biological contaminants. However, it is important for manufacturers to continue to monitor and to conduct post-marketing surveillance if they are required to release a new chemical product that might contain an ectd format or tga symbol. For more understanding of this article, visit this link: https://en.wikipedia.org/wiki/Pharmaceutical_industry.
0 Comments
10/12/2021 0 Comments Pharmaceutical Regulatory Updates: Why You Need Current Information on Drug Forms and ProductsPharmaceutical Regulatory updates are published periodically to provide the industry with information on the progress of the regulatory bodies that regulate the production, processing, and distribution of pharmaceuticals. This can be particularly useful if you are involved in the manufacture or marketing of pharmaceuticals or biologics and are involved in any type of negotiations with the FDA (Food and Drug Administration). However, it is not just important for the regulated entities to be in touch with the latest developments in the regulatory activities. It is also important for the general public to be well-informed about these activities to ensure that they have a clear understanding of the regulations that govern the manufacture, transportation, and distribution of commercial and generic products. The article provides some information on what to look out for in these documents. There are two primary sources from where you can access pharmaceutical reports. The first is the US Office of the FDA, whose web site contains a list of all current updates, which can be browsed in order. The second is the FDA's webpage on medical device regulations, which provides links to the authority's main regulating offices. Both of these sites provide comprehensive information on the activities that take place within each of the offices. Each page gives the basic overview of the category of activity, the date of the meeting, and the specifics of the product in consideration for review. In addition to accessing FDA web sites, you can also access pharmaceutical regulation information and case studies from governmental organizations like the Food and Drug Administration (FDA). The FDA web site has a search function that lets you enter a keyword to retrieve information on pending or currently pending decisions, pending legislation, and court cases. Similarly, the FTC web site allows you to search for pending decisions, proposed rules, proposed bills, and voluntary arrangements. The Federal Register is another good resource for obtaining and reviewing documents, as most of the issues that arise in pharmaceuticals are placed there. It is important to keep up to date with pharmaceutical regulatory filings. Updating your knowledge of pending legislation and cases is important for understanding the direction the pharmaceutical industry is moving. Pharmaceutical regulatory documents can be difficult to understand if you don't have specific information in front of you. With access to an electronic filing system, you can access hundreds of documents in a short period of time. If you are uncertain about any particular piece of information, contact the regulatory agency directly. They will be more than happy to explain it to you. You should also check out the company's website for helpful resources. While the company may not have all of the details you are looking for, at least you will know where to begin your search. Many pharmaceutical companies make use of formal submission tools and databases to keep in touch with their customers, suppliers, and stock. If you're not already signed up, you should consider using one or more of these tools. Pharmaceutical regulatory documents and other information can change quickly and you want to be sure you are well informed. Get a general overview of the topic here: https://en.wikipedia.org/wiki/Pharmacovigilance. To help speed up the lengthy clinical trials process for new drugs, the Pharmaceutical Research and Manufacturers of America (PRMA) proposed a plan to enable the submission of electronically signed documents, or "signatures". The proposal was not well received by the US FDA, who at first declined to regulate the use of electronic signatures as a proof of identity for medical claims. The American Medical Association and the American Association of Clinical Endocrinologists opposed the move, warning that it would enable fraudulent use of medical claims in the treatment of human diseases. It was not surprising that the FDA failed to pass the initial restriction, as the medical professions and pharmaceutical industry was busy in devising ways to protect themselves from these new technologies. However, when the New Drug Application became approved in June 2002, the FDA went back on its decision, proposing amendments that would allow biometric authentication of the medical claims made by the pharmaceutical manufacturing and pharmaceutical companies. Initially the new regulations required only that biometric information be recorded on the electronic health records (EHRs). Later, the FDA proposed to add provisions that would allow the use of electronic signature in filling out forms for new drugs, and for filing medical information. This time, however, the amendment allowed biometric data to be used to control authorization and to track and monitor the completion of long-term EHR projects. The pharmaceutical companies were not content to let this happen, and began a campaign to fight for more data security and EHR reform. The American Association of Clinical Pharmacy was particularly active in this debate, claiming that the EHR vendors were failing to protect the confidential data of their clients. Even with the FDA's revisions, the pharmaceutical companies were not entirely satisfied with the safeguards provided by the EHR and remained suspicious of the motivations of the FDA and pharmaceutical company officials. Many industry observers believe that pharmaceutical companies may eventually sue the FDA over the regulations limiting data security. Get more enlightened on the continuing education for pharmaceutical manufacturers here! Concerned parties in the pharmaceutical industry have also been exploring the possibility of developing generic drugs in an effort to reduce costs. Generic drugs are expected to cost less than those treatments designed specifically for each patient, as well as to have the same effectiveness as expensive brand-name drugs. However, these generic drugs may not be effective against some of the costly diseases affecting patients and physicians. There have also been suggestions that generic drugs may not be safe, and could possibly cause more harm than good to patients using them. The Pharmaceutical manufacturing Association has been critical of the process of biotechnology and other innovative pharmaceutical manufacturing methods, arguing that the companies are not providing data that is reliable enough to support the claims they make about their drugs. Biotechnology, for example, has been criticized for producing "clustered" or genetically engineered organisms. These organisms are not approved by the FDA and may not have the same safety and efficacy as their natural counterparts. The Association contends that the FDA should require the companies to provide more information before issuing approvals. The Biotechnology Industry Organization, another trade group, has filed a lawsuit against several biopharmaceutical companies, arguing that they are improperly controlling the genetic and environmental environments of cells used in biotechnology research. Both groups believe that the Biotechnology Industry Organization is acting inappropriately in trying to regulate the biotechnology industry. Manufactures argue that they cannot adequately control the use of antibiotics, growth hormones, medications, and other biotechnology products in the manufacturing phase of the pharmaceutical process, but they do not believe that the FDA has the authority to prohibit them from doing so. Currently, there are legal loopholes that allow biopharmaceutical plants to continue using these technologies, even though the science behind them is not fully understood. If these manufacturers lose access to the exclusive intellectual property rights associated with their technologies, it may be difficult for them to continue to manufacture the pharmaceuticals that they need, although it is unlikely that any manufacturer would go out of business due to these legal issues. Add on to your knowledge about this topic, by visiting this link: https://en.wikipedia.org/wiki/Approved_drug. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |